Media moguls: Merck KGaA squares up to Thermo and GE with $17bn Sigma buy

By Gareth Macdonald contact

- Last updated on GMT

Sigma-Aldrich HQ in St Louis, Missouri
Sigma-Aldrich HQ in St Louis, Missouri

Related tags: Emd millipore, Merck millipore

Merck KGaA has continued its diversification effort with a $17bn (€13bn) bid for Sigma Aldrich that will see it battle Thermo Fisher and GE Healthcare for a share of the life sciences tools and supplies market.

The deal – announced yesterday​ – is in keeping with Merck’s efforts to broaden its revenue streams beyond hit and miss drug development into life science supplies and technologies that began with its acquisition of EMD Millipore in 2010​.

Merck acknowledged this, explaining that the deal would expand Millipore’s global reach, citing Sigma’s established presence in both North America and fast growing Asian​ markets as drivers for the all-cash deal.

This is also the view of ISI analyst Ross Muken, who keeps a close eye on the life science tools sector.

He told BioPharma-Reporter.com “Sigma-Aldrich has a phenomenal business in China and in Asia Pacific broadly​” adding that this “should be a huge platform for growth​.”

Muken also suggested the takeover may see SAFC, Sigma-Aldrich’s fine chemicals business, and Bioreliance, its biopharma-focused testing and services unit, become more closely integrated although he did not go into specifics.

ISI’s senior managing director also commented on Merck’s statement that it intends to maintain a significant presence in Sigma-Aldrich’s home city St Louis, Missouri.

Mukan said while Merck may well keep a presence in St Louis and at its own site in Billerica, Massachusetts, “obviously there will be some headcount losses given synergy realization, but may also come from the Millipore side​.”

Small media or large

The acquisition will also impact the bioprocessing media market as Sigma Aldrich is a leading supplier alongside Sartorius Stedim Biotech, Thermo Fisher and its recent acquisition Life Technologies​ and GE Healthcare and its newly purchased Hyclone unit​.

This was acknowledged by a Merck KGaA spokesman who told BioPharma-Reporter.com "Merck Millipore [EMD Millipore in the US] already offered media and Sigma-Aldrich's position in this segment is extremely complementary to our offers to customers. So for us and the clients it makes sense as we can now offer the full value chain for biopharmaceutical production​."

Quite what the $17bn deal and the earlier Thermo and GE acquisitions, which were worth $15bn and $1bn, respectively, say about the future value of the global bioprocessing media market, which is currently valued at $5bn, is unclear.

Related news

Show more

Related products

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars